QUOTE AND NEWS
Market Intelligence Center  Apr 21  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithms on Ariad Pharmaceuticals (ARIA) could yield about 14.01% (19.01% annualized, for comparison purposes only) in 269 days. Pair a long position in the stock with the Jan....
Benzinga  Apr 18  Comment 
Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. TheStreet Senior Columnist Adam Feuerstein responded to an article in the Boston Business Journal which suggested...
Benzinga  Apr 17  Comment 
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib (AP26113), in patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung...
TheStreet.com  Apr 17  Comment 
BOSTON (TheStreet) -- In this week's Biotech Stock Mailbag, Ron D. emails, "Do you expect Bluebird Bio to have the same positive results in sickle cell disease that they had with beta-thalassemia? When will the company tell us about its sickle...
Benzinga  Mar 24  Comment 
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig®...
Market Intelligence Center  Mar 6  Comment 
Ariad Pharmaceuticals (ARIA) was selected by MarketIntelligenceCenter.com’s trade-picking algorithms today after trading between $8.25 and $8.65 on Thursday before closing at $8.25. A diagonal spread using a long position in the Jan. '16 $5.00...
Motley Fool  Mar 5  Comment 
Ariad Pharmaceuticals' shares rocket to their highest levels since last Spring following a double-dose of positive news for shareholders. Find out whether this momentum can continue.
Motley Fool  Feb 20  Comment 
Ariad Pharmaceuticals shares are jumping following its earnings yesterday and news of an upcoming proxy fight.




 

Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.





References

Morningstar.com

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki